EN DE
Watch Yuhan Corp. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Yuhan Corp. (000100) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Yuhan Corp. stock KRW 28,619, price KRW 81,300, that is 64.8% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7000100008

YC Yuhan Corp. logo Some data Nov 20, 2026

Yuhan Corp.

000100 · KO

Far too expensive (fair value 65% below the price) and falling price, but solid company: meets 1 of 3 rules.

Follow free in the weekly email
Solidly profitable · 10.4% net margin (TTM) 
Low debt 
Profit last quarter +55% vs. a year ago. 
Quality 55/100 
Expensive Growth (revenue 5y +6.2 %/yr in KRW) 
0.7% dividend yield · Token dividend
Mixed vs. peers (6/13) 
Moderate moat 46/100 · thin data
Some data 
Changed on Oct 30: ₩44,818 → ₩28,619 
Fair value 28,619 KRW · Strongly overvalued 
Falling price (downtrend) 
Negative free cash flow 
Watch Yuhan Corp. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

162,125 KRW 46,936 KRW Fair Value 28,619 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.

How to read this chart

60‑month range 46,936 KRW – 162,125 KRW · fair‑value band 26,604 KRW – 33,636 KRW · the 81,300 KRW price screens above the 28,619 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.

Follow Yuhan in your weekly email

Every Wednesday you see whether Yuhan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally.

Show moreShow less

It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support.

The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others.

Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

Stock analysis

Yuhan Corp. (000100) currently trades at 81,300 KRW, while our model-based Fair Value estimate is 28,619 KRW, 65% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 52,638 KRW per share, and 1 of the 16 models we run sit above the 81,300 KRW price.

Bear case: the Asset-Based group reads lowest at 8,117 KRW, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 26,604 KRW (bear) to 33,636 KRW (bull), the price of 81,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Yuhan Corp. reported revenue of 2.2T KRW in FY2025 versus 1.7T KRW in FY2021, a compound +6.7%/yr. Reported net income was 194B KRW in FY2025, compounding +17.3%/yr from FY2021.

Key figures

Market cap 6.0T KRW (≈ $4.5B) Mid · P/E ratio 25.6 · P/S ratio 2.62 · EPS (TTM) 3,131 KRW · Dividend yield 0.7% · Net margin 10.4% · Return on equity 9.5% · Return on assets (EBIT) 2.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 33% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −65%, 000100 screens richer than that median.

Fair Value models

Bear 26,604 KRW Fair Value 28,619 KRW Bull 33,636 KRW
Price 81,300 KRW · Downside -64.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (2,247 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 26,604 KRW 28,619 KRW 33,636 KRW 76
EPV 16,071 KRW 18,151 KRW 19,978 KRW 74
ROIC Compounder 16,071 KRW 18,151 KRW 19,978 KRW 72
All 16 models by family
Earnings-Based
Graham-Dodd 17,927 KRW 60,630 KRW 81,276 KRW 64
Lynch FV 17,597 KRW 25,139 KRW 32,680 KRW 61
PEG = 1.0 17,597 KRW 25,139 KRW 32,680 KRW 57
EPV 16,071 KRW 18,151 KRW 19,978 KRW 74
Dividend Discount
Gordon GGM 5,216 KRW 10,975 KRW 17,649 KRW 66
DDM Multi-Stage 5,216 KRW 9,008 KRW 11,499 KRW 66
Multiples
P/E Multiple 43,500 KRW 58,000 KRW 72,500 KRW 63
P/S Multiple 33,614 KRW 44,818 KRW 56,023 KRW 58
P/B Multiple 92,018 KRW 122,690 KRW 153,363 KRW 55
EV/EBIT 21,846 KRW 27,872 KRW 33,898 KRW 66
EV/EBITDA 28,520 KRW 36,770 KRW 45,021 KRW 67
EV/Revenue 16,671 KRW 22,201 KRW 27,730 KRW 54
Asset-Based
NCAV (Graham) 5,357 KRW 8,117 KRW 10,146 KRW 54
Economic Profit
Residual Income 26,604 KRW 28,619 KRW 33,636 KRW 76
ROIC Compounder 16,071 KRW 18,151 KRW 19,978 KRW 72
Growth Earnings
Growth-Adj P/E 36,847 KRW 52,638 KRW 68,430 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 68
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 45/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: +6.8% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.2%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.6% vs −0.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
2025 sits 95% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)

000100 screens overvalued: fair value 65% below the price. Compare with Merck KGaA →

Compare Yuhan Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −64.8% · Bottom 25%
Profitability
Return on equity (12 months) 9.5% · Above median
Return on assets 6.0% · Above median
Net margin (12 months) 10.4% · Above median
Operating margin (12 months) 5.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 10.4% · Above median
Dividend yield (12 months) 0.7% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 25.6× · Pricier than median
P/B 2.59× · Pricier than median
P/S (12 months) 2.62× · Pricier than median
EV/EBITDA 28.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)52 · sector 29
PAST (return on equity)38 · sector 26
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)15 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $80.79 $113.53 +41% vs 000100
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 000100
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 000100
Haleon plc HLN $9.05 $8.47 −6% vs 000100
Merck KGaA MRK €148.40 €108.83 −27% vs 000100
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 000100
Teva Pharmaceutical Industries Limited TEVA $38.54 $20.74 −46% vs 000100
Takeda Pharmaceutical Company TAK $21.41 $11.23 −48% vs 000100
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 000100
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 000100

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Yuhan Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Yuhan Corp. Fair Value". https://www.fairvalue-calculator.com/stock/000100.KO

Frequently asked questions

Is Yuhan Corp. (000100) overvalued or undervalued?
As of Nov 20, 2026, our model estimates a fair value of 28,619 KRW versus a price of 81,300 KRW, about 65% lower (overvalued).
What is the fair value of 000100?
Our model-based fair value for Yuhan Corp. is 28,619 KRW (as of Nov 20, 2026), built from audited fundamentals. The current price: 81,300 KRW.
What is the quality score of 000100?
Yuhan Corp. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yuhan Corp. (000100)?
We do not set a price target; the yardstick is the fair value of 28,619 KRW (as of Nov 20, 2026) from 16 valuation models. Cautious scenario 26,604 KRW, optimistic scenario 33,636 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Yuhan Corp. stock forecast for 2026?
Our models put fair value at 28,619 KRW, about 65% lower versus a price of 81,300 KRW (overvalued). Cautious scenario 26,604 KRW, optimistic scenario 33,636 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Yuhan Corp. (000100)?
Yuhan Corp. reported trailing-twelve-month revenue of about 2.3T KRW (latest available figure, as of Nov 20, 2026).
Does Yuhan Corp. pay a dividend?
Yuhan Corp. currently shows a dividend yield of 0.74% relative to its recent price (as of Nov 20, 2026).
How much is the dividend of Yuhan Corp. (000100) and when is the ex-dividend date?
Yuhan Corp. pays a dividend of 600.00 KRW per share a year, a dividend yield of 0.7%. The last ex-dividend date was Feb 26, 2026. The payout ratio is 19.2% of earnings. Our assessment: Token dividend. At a yield of 0.7% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.7% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Yuhan Corp. (000100)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yuhan Corp. it is 28,619 KRW per share (as of Nov 20, 2026), against a price of 81,300 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Yuhan Corp. stock overvalued or undervalued in 2026?
As of Nov 20, 2026, 000100 trades above its calculated fair value: price 81,300 KRW, fair value 28,619 KRW, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000100?
No. The price is what the market pays today (81,300 KRW); the fair value is what the company's own numbers justify (28,619 KRW). For Yuhan Corp. the two are 52,681 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Yuhan Corp. worth?
The market values Yuhan Corp. at about 6.0T KRW (market capitalisation, as of Nov 20, 2026). Per share that is 81,300 KRW; our models calculate a fair value of 28,619 KRW per share.
What do the bullish and bearish scenarios say about 000100?
Our models span a range for Yuhan Corp.: cautious scenario 26,604 KRW, base 28,619 KRW, optimistic 33,636 KRW per share (as of Nov 20, 2026, price 81,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000100?
Yuhan Corp. trades at a price-to-earnings ratio of 25.6 (as of Nov 20, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 28,619 KRW is built from several models across several years. Other multiples: P/B 2.6, P/S 2.6, EV/EBITDA 28.2.
How solid is the balance sheet of Yuhan Corp. (000100)?
Balance-sheet figures for Yuhan Corp. (as of Nov 20, 2026): return on equity 9.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 000100 from its 52-week high?
Yuhan Corp. trades at 81,300 KRW, about 33% below its 52-week high of 121,353 KRW and 22% above the low of 66,400 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 28,619 KRW is for.
Which stocks are comparable to Yuhan Corp.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yuhan Corp. stock attractive at the current price?
The data as of Nov 20, 2026: price 81,300 KRW, calculated fair value 28,619 KRW (−65%), Quality Score 55/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000100 calculated?
We run Yuhan Corp. through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 28,619 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Yuhan Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yuhan Corp. (000100)?
The closing price on Nov 19, 2026 was 81,300 KRW. Our model-based fair value is 28,619 KRW, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yuhan Corp. right now?
The price sits above even our optimistic bull case (33,636 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Yuhan Corp.

How large is the market capitalisation of Yuhan Corp. (000100)?
The market capitalisation of Yuhan Corp. is 6.0T KRW (≈ $4.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yuhan Corp. (000100)?
The price-to-sales ratio of Yuhan Corp. is 2.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yuhan Corp. (000100)?
Earnings per share at Yuhan Corp. are 3,131 KRW (price ÷ EPS = P/E 25.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Yuhan Corp. (000100)?
The dividend yield of Yuhan Corp. is 0.7% (payout 19.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Yuhan Corp. (000100)?
The net margin of Yuhan Corp. is 10.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yuhan Corp. (000100)?
The return on equity (ROE) of Yuhan Corp. is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yuhan Corp. (000100)?
On an EBIT basis the return on assets of Yuhan Corp. is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yuhan Corp. (000100)?
The operating margin of Yuhan Corp. is 5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yuhan Corp. (000100)?
Revenue at Yuhan Corp. is growing 10.4% versus a year earlier (3y avg +7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yuhan Corp. (000100)?
Earnings per share at Yuhan Corp. are growing 54.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yuhan Corp. (000100) generate?
The free cash flow of Yuhan Corp. is −38.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Yuhan Corp. in the live analysis

One click puts Yuhan Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.